Objective response at week 25 was 54% with pimicotinib versus 3% with placebo, supporting robust antitumor activity in unresectable TGCT. Patient-reported endpoints showed meaningful improvements in ...
Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss—No Target Is Out of the Realm of Possibility Bispecific antibodies (bsAbs) have emerged as a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results